NAMI-A is a ruthenium(III)-based coordination complex, chemically known as imidazolium trans-[tetrachlorodimethylsulfoxide-1-imidazolium ruthenate(II)] or [ImH][RuCl₄(DMSO)Im], primarily researched for its potential applications in cancer treatment, particularly in combating metastatic cancers. It has shown promise in inhibiting the spread of cancer cells to other parts of the body, a process known as metastasis, rather than directly killing the cancer cells. This makes it a unique candidate for combination therapies, where it can be used alongside other treatments that target tumor growth. Its mechanism involves interfering with the tumor microenvironment and angiogenesis, which are critical for cancer progression. Clinical studies are ongoing to explore its efficacy and safety in treating various types of cancers, including lung and breast cancer.